Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

ICU patients may need custom doses of common antifungal

NCT ID NCT02164890

Knowledge-focused Sponsor: University Hospital, Limoges Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the antifungal drug micafungin is processed in the bodies of 60 critically ill ICU patients with invasive candidiasis. Researchers took multiple blood samples to measure drug levels and understand why some patients might not get enough medicine. The goal is to improve dosing for this vulnerable group.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
micafungin
What this could lead to
If successful, this could help doctors tailor micafungin doses for ICU patients, potentially improving treatment success.
What could go wrong
This is a small, completed pharmacokinetic study, not a treatment trial. It may not lead to new dosing guidelines or directly improve patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

60 people

The number who actually took part.

Started

Jun 2014

Finished

Dec 2016

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Critically ill patients hospitalized in an ICU, with suspected or proven invasive fungal infections, for whom the decision has been made to start a treatment based on MCF. * Age \> 18 years. * Patients willing to give their written informed consent for their participation to the study. * Patients affiliated to the French social security system or equivalent. Exclusion Criteria: * Patient for whom a treatment based on MCF has already been started * Patient who have benefited from bone marrow transplantation * Age \< 18 years * Patient under legal protection * Patient deprived of liberty * Pregnant or breast-feeding woman or woman of childbearing potential without efficient contraception (based on declaration) * Patient with any altered mental status or any psychiatric condition that would interfere with the understanding of the study * Patient enrolled in another clinical trial testing drugs or therapeutic strategies (including the so-called "exclusion period")

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Invasive candidiasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

candidiasis, invasive disseminated candidiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Invasive candidiasis

Contacts and locations

Locations

  • CHU de Montpellier

    Montpellier, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.